Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine

References

• Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 68(5), 343–349 (2007).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 41, 646–657 (2001).
   PubMed Web of Science ®Google Scholar
• Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 290(18), 2443–2454 (2003).
   PubMed Web of Science ®Google Scholar
• Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur. J. Neurol. 12(Suppl 1), 1–27 (2005).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Lipton RB, Ferrari MD. Migraine–current understanding and treatment. N. Engl. J. Med. 346(4), 257–270 (2002).
   PubMed Web of Science ®Google Scholar
• Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J. Clin. Neurol. 8(2), 89–99 (2012).
   PubMed Web of Science ®Google Scholar
• Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat. Rev. Neurosci. 12(10), 570–584 (2011).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR. Neurobiology of migraine. Neuroscience 161(2), 327–341 (2009).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 114(Pt 2), 1001–1011 (1991).
   PubMedGoogle Scholar
• Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ. Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res. 629(1), 95–102 (1993).
   PubMed Web of Science ®Google Scholar
• Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J. Neurophysiol. 79(2), 964–982 (1998).
   PubMed Web of Science ®Google Scholar
• Bartsch T, Goadsby PJ. The trigeminocervical complex and migraine: current concepts and synthesis. Curr. Pain Headache Rep. 7(5), 371–376 (2003).
   PubMedGoogle Scholar
• Johnston MM, Jordan SE, Charles AC. Pain referral patterns of the C1-C3 nerves: Implications for headache disorders. Ann. Neurol. (2013).
   Web of Science ®Google Scholar
• Bartsch T, Goadsby PJ. Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain 125(Pt 7), 1496–1509 (2002).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Knight YE, Hoskin KL. Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. Pain 73(1), 23–28 (1997).
   PubMed Web of Science ®Google Scholar
• Bartsch T, Goadsby PJ. Anatomy and physiology of pain referral in primary and cervicogenic headache disorders. Headache Curr. 2, 42–48 (2005).
   Google Scholar
• Malick A, Burstein R. Cells of origin of the trigeminohypothalamic tract in the rat. J. Comp. Neurol. 400(1), 125–144 (1998).
   PubMed Web of Science ®Google Scholar
• Malick A, Strassman RM, Burstein R. Trigeminohypothalamic and reticulohypothalamic tract neurons in the upper cervical spinal cord and caudal medulla of the rat. J. Neurophysiol. 84(4), 2078–2112 (2000).
   PubMed Web of Science ®Google Scholar
• Malick A, Jakubowski M, Elmquist JK, Saper CB, Burstein R. A neurohistochemical blueprint for pain-induced loss of appetite. Proc. Natl Acad. Sci. USA 98(17), 9930–9935 (2001).
   PubMed Web of Science ®Google Scholar
• Benjamin L, Levy MJ, Lasalandra MP et al. Hypothalamic activation after stimulation of the superior sagittal sinus in the cat: a Fos study. Neurobiol. Dis. 16(3), 500–505 (2004).
   PubMed Web of Science ®Google Scholar
• Liu Y, Broman J, Zhang M, Edvinsson L. Brainstem and thalamic projections from a craniovascular sensory nervous centre in the rostral cervical spinal dorsal horn of rats. Cephalalgia 29(9), 935–948 (2009).
   PubMed Web of Science ®Google Scholar
• Matsushita M, Ikeda M, Okado N. The cells of origin of the trigeminothalamic, trigeminospinal and trigeminocerebellar projections in the cat. Neuroscience 7(6), 1439–1454 (1982).
   PubMed Web of Science ®Google Scholar
• Shigenaga Y, Nakatani Z, Nishimori T, Suemune S, Kuroda R, Matano S. The cells of origin of cat trigeminothalamic projections: especially in the caudal medulla. Brain Res. 277(2), 201–222 (1983).
   PubMed Web of Science ®Google Scholar
• Knight YE, Classey JD, Lasalandra MP et al. Patterns of fos expression in the rostral medulla and caudal pons evoked by noxious craniovascular stimulation and periaqueductal gray stimulation in the cat. Brain Res. 1045 (1–2), 1–11 (2005).
   PubMed Web of Science ®Google Scholar
• Hoskin KL, Bulmer DCE, Lasalandra M, Jonkman A, Goadsby PJ. Fos expression in the midbrain periaqueductal grey after trigeminovascular stimulation. J. Anat. 198, 29–35 (2001).
   PubMed Web of Science ®Google Scholar
• Lambert GA, Hoskin KL, Zagami AS. Cortico-NRM influences on trigeminal neuronal sensation. Cephalalgia 28(6), 640–652 (2008).
   PubMed Web of Science ®Google Scholar
• Edelmayer RM, Vanderah TW, Majuta L et al. Medullary pain facilitating neurons mediate allodynia in headache-related pain. Ann. Neurol. 65(2), 184–193 (2009).
   PubMed Web of Science ®Google Scholar
• Kaube H, Hoskin KL, Goadsby PJ. Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat [see comments]. Cephalalgia 12(3), 133–136 (1992).
   PubMed Web of Science ®Google Scholar
• Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 384(6609), 560–564 (1996).
   PubMed Web of Science ®Google Scholar
• Romero-Reyes M, Akerman S, Nguyen E et al. Spontaneous Behavioral Responses in the Orofacial Region: A Model of Trigeminal Pain in Mouse. Headache 53(1), 137–151 (2013).
   PubMed Web of Science ®Google Scholar
• Akerman S, Holland PR, Lasalandra MP, Goadsby PJ. Oxygen inhibits neuronal activation in the trigeminocervical complex after stimulation of trigeminal autonomic reflex, but not during direct dural activation of trigeminal afferents. Headache 49(8), 1131–1143 (2009).
   PubMed Web of Science ®Google Scholar
• Akerman S, Holland PR, Summ O, Lasalandra MP, Goadsby PJ. A translational in vivo model of trigeminal autonomic cephalalgias: therapeutic characterization. Brain 135(Pt 12), 3664–3675 (2012).
   PubMedGoogle Scholar
• Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann. Neurol. 56(3), 371–381 (2004).
   PubMed Web of Science ®Google Scholar
• Knight YE, Goadsby PJ. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine?Neuroscience 106(4), 793–800 (2001).
   PubMed Web of Science ®Google Scholar
• Knight YE, Bartsch T, Kaube H, Goadsby PJ. P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J. Neurosci. 22(5), RC213 (2002).
   PubMed Web of Science ®Google Scholar
• Bartsch T, Levy MJ, Knight YE, Goadsby PJ. Inhibition of nociceptive dural input in the trigeminal nucleus caudalis by somatostatin receptor blockade in the posterior hypothalamus. Pain 117 (1–2), 30–39 (2005).
   PubMed Web of Science ®Google Scholar
• Bartsch T, Levy MJ, Knight YE, Goadsby PJ. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 109(3), 367–378 (2004).
   PubMed Web of Science ®Google Scholar
• Magis D, Schoenen J. Advances and challenges in neurostimulation for headaches. Lancet Neurol. 11(8), 708–719 (2012).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. The pharmacology of headache. Prog. Neurobiol. 62(5), 509–525 (2000).
   PubMed Web of Science ®Google Scholar
• Aurora SK, Rozen TD, Kori SH, Shrewsbury SB. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 49(6), 826–837 (2009).
   PubMed Web of Science ®Google Scholar
• Ferrari MD. Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N. Engl. J. Med. 325(5), 316–321 (1991).
   PubMed Web of Science ®Google Scholar
• Humphrey PP, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol. Sci. 12(12), 444–446 (1991).
   PubMed Web of Science ®Google Scholar
• Moskowitz MA. The neurobiology of vascular head pain. Ann. Neurol. 16(2), 157–168 (1984).
   PubMed Web of Science ®Google Scholar
• Moskowitz MA. Basic mechanisms in vascular headache. Neurol. Clin. 8(4), 801–815 (1990).
   PubMed Web of Science ®Google Scholar
• Longmore J, Shaw D, Smith D et al. Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 17(8), 833–842 (1997).
   PubMed Web of Science ®Google Scholar
• Razzaque Z, Heald MA, Pickard JD et al. Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. Br. J. Clin. Pharmacol. 47(1), 75–82 (1999).
   PubMed Web of Science ®Google Scholar
• Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br. J. Pharmacol. 99(1), 202–206 (1990).
   PubMed Web of Science ®Google Scholar
• Longmore J, Boulanger CM, Desta B, Hill RG, Schofield WN, Taylor AA. 5-HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br. J. Clin. Pharmacol. 42(4), 431–441 (1996).
   PubMed Web of Science ®Google Scholar
• Longmore J, Hargreaves RJ, Boulanger CM et al. Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. Funct. Neurol. 12(1), 3–9 (1997).
   PubMed Web of Science ®Google Scholar
• Nilsson T, Longmore J, Shaw D et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur. J. Pharmacol. 372(1), 49–56 (1999).
   PubMed Web of Science ®Google Scholar
• Gupta P, Brown D, Butler P et al. The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation. Br. J. Pharmacol. 116(5), 2385–2390 (1995).
   PubMed Web of Science ®Google Scholar
• Lee WS, Moskowitz MA. Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res. 626(1–2), 303–305 (1993).
   PubMed Web of Science ®Google Scholar
• Giles H, Honey A, Edvinsson L, Selwood D, Cambridge D, Martin GR. Pre-clinical pharmacology of 4991w93, a potent inhibitor of neurogenic plasma protein extravasation. Cephalalgia 19, 402 (1999).
   Web of Science ®Google Scholar
• Earl NL, McDonald SA, Lowry MT. Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93 in the acute treatment of migraine. Cephalalgia 19, 357 (1999).
   Web of Science ®Google Scholar
• Roon KI, Olesen J, Diener HC et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. Ann. Neurol. 47(2), 238–241 (2000).
   PubMed Web of Science ®Google Scholar
• Harriott AM, Gold MS. Serotonin type 1D receptors (5HTR) are differentially distributed in nerve fibres innervating craniofacial tissues. Cephalalgia 28(9), 933–944 (2008).
   PubMed Web of Science ®Google Scholar
• Ma QP. Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport 12(8), 1589–1591 (2001).
   PubMed Web of Science ®Google Scholar
• Ma QP, Hill R, Sirinathsinghji D. Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats. Eur. J. Neurosci. 13(11), 2099–2104 (2001).
   PubMed Web of Science ®Google Scholar
• Smith D, Shaw D, Hopkins R et al. Development and characterisation of human 5-HT1B- or 5-HT1D-receptor specific antibodies as unique research tools. J. Neurosci. Methods 80(2), 155–161 (1998).
   PubMed Web of Science ®Google Scholar
• Smith D, Hill RG, Edvinsson L, Longmore J. An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia 22(6), 424–431 (2002).
   PubMed Web of Science ®Google Scholar
• Castro ME, Pascual J, Romon T, del Arco C, del Olmo E, Pazos A. Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord. Neuropharmacology 36(4–5), 535–542 (1997).
   PubMed Web of Science ®Google Scholar
• Pascual J, Del Arco C, Romon T, Del Olmo E, Pazos A. [3H]Sumatriptan binding sites in human brain: regional-dependent labelling of 5-HT1D and 5-HT1F receptors. Eur. J. Pharmacol. 295(2–3), 271–274 (1996).
   PubMed Web of Science ®Google Scholar
• Mills A, Martin GR. Autoradiographic mapping of [3H]sumatriptan binding in cat brain stem and spinal cord. Eur. J. Pharmacol. 280(2), 175–178 (1995).
   PubMed Web of Science ®Google Scholar
• Waeber C, Moskowitz MA. [3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study. Naunyn. Schmiedebergs Arch. Pharmacol. 352(3), 263–275 (1995).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat [see comments]. Cephalalgia 17(3), 153–158 (1997).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Hoskin KL. Differential effects of low dose CP122,288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in cat. Pain 82(1), 15–22 (1999).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Knight YE. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors. Br. J. Pharmacol. 122(5), 918–922 (1997).
   PubMed Web of Science ®Google Scholar
• Cumberbatch MJ, Hill RG, Hargreaves RJ. Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia 18(10), 659–663 (1998).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain 67(2–3), 355–359 (1996).
   PubMed Web of Science ®Google Scholar
• Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur. J. Pharmacol. 328(1), 37–40 (1997).
   PubMed Web of Science ®Google Scholar
• Cumberbatch MJ, Hill RG, Hargreaves RJ. The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats. Eur. J. Pharmacol. 362(1), 43–46 (1998).
   PubMed Web of Science ®Google Scholar
• Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br. J. Pharmacol. 109(3), 788–792 (1993).
   PubMed Web of Science ®Google Scholar
• Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc. Natl Acad. Sci. USA 101(12), 4274–4279 (2004).
   PubMed Web of Science ®Google Scholar
• Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann. Neurol. 55(1), 27–36 (2004).
   PubMed Web of Science ®Google Scholar
• Cutrer FM, Yu XJ, Ayata G, Moskowitz MA, Waeber C. Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis. Neuropharmacology 38(7), 1043–1053 (1999).
   PubMed Web of Science ®Google Scholar
• Gomez-Mancilla B, Cutler NR, Leibowitz MT et al. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia 21(7), 727–732 (2001).
   PubMed Web of Science ®Google Scholar
• Storer RJ, Goadsby PJ. Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 120(Pt 12), 2171–2177 (1997).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Akerman S, Storer RJ. Evidence for postjunctional serotonin (5-HT1) receptors in the trigeminocervical complex. Ann. Neurol. 50(6), 804–807 (2001).
   PubMed Web of Science ®Google Scholar
• Shields KG, Goadsby PJ. Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol. Dis. 23, 491–501 (2006).
   PubMed Web of Science ®Google Scholar
• Pfaffenrath V, Scherzer S. Analgesics and NSAIDs in the treatment of the acute migraine attack. Cephalalgia 15(Suppl 15.), 14–20 (1995).
   PubMed Web of Science ®Google Scholar
• Zeilhofer HU, Brune K. Analgesic strategies beyond the inhibition of cyclooxygenases. Trends Pharmacol. Sci. 27(9), 467–474 (2006).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Cittadini E, Burns B, Cohen AS. Trigeminal autonomic cephalalgias-diagnostic and therapeutic developments. Current Opinion in Neurology. 21, 323–330 (2008).
   PubMed Web of Science ®Google Scholar
• Summ O, Andreou AP, Akerman S, Hoffmann J, Goadsby PJ. Effects of indomethacin, naproxen and ibuprofen on no-induced trigeminal firing recorded in the trigeminocervical complex. Cephalalgia 31(S1), 10 (2011).
   Google Scholar
• Smith CJ, Zhang Y, Koboldt CM et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl Acad. Sci. USA 95(22), 13313–13318 (1998).
   PubMed Web of Science ®Google Scholar
• Riendeau D, Percival MD, Boyce S et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. 121(1), 105–117 (1997).
   PubMed Web of Science ®Google Scholar
• Vanegas HN, Schaible HG. Prostaglandins and cycloxygenases in the spinal cord. Prog. Neurobiol. 64(4), 327–363 (2001).
   PubMed Web of Science ®Google Scholar
• Myren M, Baun M, Ploug KB, Jansen-Olesen I, Olesen J, Gupta S. Functional and molecular characterization of prostaglandin E2 dilatory receptors in the rat craniovascular system in relevance to migraine. Cephalalgia 30(9), 1110–1122 (2012).
   Web of Science ®Google Scholar
• Zhang XC, Kainz V, Jakubowski M, Burstein R, Strassman A, Levy D. Localization of COX-1 and COX-2 in the intracranial dura mater of the rat. Neurosci. Lett. 452(1), 33–36 (2009).
   PubMed Web of Science ®Google Scholar
• Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandin E2 induces immediate migraine-like attack in migraine patients without aura. Cephalalgia 32(11), 822–833 (2012).
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 20(10), 907–918 (2000).
   PubMed Web of Science ®Google Scholar
• Wienecke T, Olesen J, Ashina M. Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs. Cephalalgia 30(2), 179–190 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang XC, Strassman AM, Burstein R, Levy D. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J. Pharmacol. Exp. Ther. 322(2), 806–812 (2007).
   PubMed Web of Science ®Google Scholar
• Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 45(7), 850–861 (2005).
   PubMed Web of Science ®Google Scholar
• Levy D, Zhang XC, Jakubowski M, Burstein R. Sensitization of meningeal nociceptors: inhibition by naproxen. Eur. J. Neurosci. 27(4), 917–922 (2008).
   PubMed Web of Science ®Google Scholar
• Bergerot A, Holland PR, Akerman S et al. Animal models of migraine: looking at the component parts of a complex disorder. Eur. J. Neurosci. 24(6), 1517–1534 (2006).
   PubMed Web of Science ®Google Scholar
• Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport 4(8), 1027–1030 (1993).
   PubMed Web of Science ®Google Scholar
• Iversen HK, Olesen J, Tfelt-hansen P. Intravenous Nitroglycerin As an Experimental-Model of Vascular Headache - Basic Characteristics. Pain 38(1), 17–24 (1989).
   PubMed Web of Science ®Google Scholar
• Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 22(1), 54–61 (2002).
   PubMed Web of Science ®Google Scholar
• Akerman S, Williamson DJ, Kaube H, Goadsby PJ. The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. Eur. J. Pharmacol. 452(2), 223–228 (2002).
   PubMed Web of Science ®Google Scholar
• Summ O, Andreou AP, Akerman S, Goadsby PJ. A potential nitrergic mechanism of action for indomethacin, but not other COX inhibitors - relevance to indomethacin-sensitive headaches. J. Headache Pain 11(6), 477–483 (2010).
   PubMed Web of Science ®Google Scholar
• May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J. Cereb. Blood Flow Metab. 19(2), 115–127 (1999).
   PubMed Web of Science ®Google Scholar
• Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 28(3), 226–236 (2008).
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Joseph SA. Systemic Nitroglycerin Induces Fos Immunoreactivity in Brain- Stem and Forebrain Structures of the Rat. Brain Res. 682(1–2), 167–181 (1995).
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Greco R, Armentero MT, Blandini F, Sandrini G, Nappi G. A role for brain cyclooxygenase-2 and prostaglandin-E2 in migraine: effects of nitroglycerin. Int. Rev. Neurobiol. 82, 373–382 (2007).
   PubMed Web of Science ®Google Scholar
• Ellrich J, Schepelmann K, Pawlak M, Messlinger K. Acetylsalicylic acid inhibits meningeal nociception in rat. Pain 81(1–2), 7–14 (1999).
   PubMed Web of Science ®Google Scholar
• Kaube H, Hoskin KL, Goadsby PJ. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 33(10), 541–544 (1993).
   PubMed Web of Science ®Google Scholar
• Jakubowski M, Levy D, Kainz V, Zhang XC, Kosaras B, Burstein R. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience 148(2), 573–583 (2007).
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW et al. Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine. N. Engl. J. Med. 350(11), 1104–1110 (2004).
   PubMed Web of Science ®Google Scholar
• Ho TW, Mannix LK, Fan X et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70(16), 1304–1312 (2008).
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Aurora SK, Dodick DW et al. Randomized controlled trial of the CGRP receptor antagonist, MK-3207, in the acute treatment of migraine. Cephalalgia 31, (2011) (in press).
   Web of Science ®Google Scholar
• Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 31(5), 573–584 (2011).
   PubMed Web of Science ®Google Scholar
• Han TH, Blanchard RL, Palcza J et al. Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J. Clin. Pharmacol. 50(12), 1367–1376 (2010).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. 23(2), 193–196 (1988).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28(2), 183–187 (1990).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 33(1), 48–56 (1993).
   PubMed Web of Science ®Google Scholar
• Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 16(2), 69–75 (1990).
   PubMed Web of Science ®Google Scholar
• Lennerz JK, Ruhle V, Ceppa EP et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J. Comp. Neurol. 507(3), 1277–1299 (2008).
   PubMed Web of Science ®Google Scholar
• Kurosawa M, Messlinger K, Pawlak M, Schmidt RF. Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin gene-related peptide. Br. J. Pharmacol. 114(7), 1397–1402 (1995).
   PubMed Web of Science ®Google Scholar
• Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia 17(4), 518–524(1997a).
   PubMed Web of Science ®Google Scholar
• Troltzsch M, Denekas T, Messlinger K. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. Eur. J. Pharmacol. 562(1–2), 103–110 (2007).
   PubMed Web of Science ®Google Scholar
• Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat–intravital microscope studies. Cephalalgia 17(4), 525–531 (1997b).
   PubMed Web of Science ®Google Scholar
• Levy D, Burstein R, Strassman AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann. Neurol. 58(5), 698–705 (2005).
   PubMed Web of Science ®Google Scholar
• Cumberbatch MJ, Williamson DJ, Mason GS, Hill RG, Hargreaves RJ. Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist. Br. J. Pharmacol. 126(6), 1478–1486 (1999).
   PubMed Web of Science ®Google Scholar
• Fischer MJ, Koulchitsky S, Messlinger K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J. Neurosci. 25(25), 5877–5883 (2005).
   PubMed Web of Science ®Google Scholar
• Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br. J. Pharmacol. 142(7), 1171–1181 (2004).
   PubMed Web of Science ®Google Scholar
• Summ O, Charbit AR, Andreou AP, Goadsby PJ. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain 133(9), 2540–2548 (2010).
   PubMed Web of Science ®Google Scholar
• Zeller J, Poulsen KT, Sutton JE et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br. J. Pharmacol. 155(7), 1093–1103 (2008).
   PubMed Web of Science ®Google Scholar
• Juhl L, Edvinsson L, Olesen J, Jansen-Olesen I. Effect of two novel CGRP-binding compounds in a closed cranial window rat model. Eur. J. Pharmacol. 567(1–2), 117–124 (2007).
   PubMed Web of Science ®Google Scholar
• Brandes JL, Jacobs D, Neto W, Bhattacharaya S. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, parallel study. Neurology 60(Suppl. 1), A238 (2003).
   Google Scholar
• Diener HC, Tfelt-Hansen P, Dahlof C et al. Topiramate in migraine prophylaxis–results from a placebo-controlled trial with propranolol as an active control. J. Neurol. 251(8), 943–950 (2004).
   PubMed Web of Science ®Google Scholar
• Edwards KR, Potter DL, Wu SC, Kamin M, Hulihan J. Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectr. 8(6), 428–432 (2003).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. 61(4), 490–495 (2004).
   PubMedGoogle Scholar
• Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41(Suppl. 1), S3–S9 (2000).
   PubMed Web of Science ®Google Scholar
• Dalkara T, Nozari A, Moskowitz MA. Migraine aura pathophysiology: the role of blood vessels and microembolisation. Lancet Neurol. 9(3), 309–317 (2010).
   PubMed Web of Science ®Google Scholar
• Eikermann-Haerter K, Moskowitz MA. Animal models of migraine headache and aura. Curr. Opin. Neurol. 21(3), 294–300 (2008).
   PubMed Web of Science ®Google Scholar
• Eikermann-Haerter K, Ayata C. Cortical spreading depression and migraine. Curr. Neurol. Neurosci. Rep. 10(3), 167–173 (2010).
   PubMed Web of Science ®Google Scholar
• Wolthausen J, Sternberg S, Gerloff C, May A. Are cortical spreading depression and headache in migraine causally linked?Cephalalgia 29(2), 244–249 (2009).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. Migraine, aura and cortical spreading depression: why are we still talking about it? Ann. Neurol. 49, 4–6 (2001).
   PubMed Web of Science ®Google Scholar
• Ayata C. Cortical spreading depression triggers migraine attack: pro. Headache 50(4), 725–730 (2010).
   PubMed Web of Science ®Google Scholar
• Charles A. Does cortical spreading depression initiate a migraine attack? Maybe not. Headache 50(4), 731–733 (2010).
   PubMed Web of Science ®Google Scholar
• Leao AAP. Spreading depression of activity in cerebral cortex. J. Neurophysiol. 7, 359–390 (1944).
   Google Scholar
• Leao AAP. Pial circulation and spreading activity in the cerebral cortex. J. Neurophysiol. 7, 391–396 (1944).
   Google Scholar
• Akerman S, Goadsby PJ. Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. Neuroreport 16(12), 1383–1387 (2005).
   PubMed Web of Science ®Google Scholar
• Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 59(4), 652–661 (2006).
   PubMed Web of Science ®Google Scholar
• Akerman S, Goadsby PJ. Topiramate inhibits trigeminovascular activation: an intravital microscopy study. Br. J. Pharmacol. 146(1), 7–14 (2005).
   PubMed Web of Science ®Google Scholar
• Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 24(12), 1049–1056 (2004).
   PubMed Web of Science ®Google Scholar
• Andreou AP, Goadsby PJ. Topiramate in the treatment of migraine: a kainate (glutamate) receptor antagonist within the trigeminothalamic pathway. Cephalalgia 31(13), 1343–1358 (2011).
   PubMed Web of Science ®Google Scholar
• Knight YE, Bartsch T, Goadsby PJ. Trigeminal antinociception induced by bicuculline in the periaqueductal gray (PAG) is not affected by PAG P/Q-type calcium channel blockade in rat. Neurosci. Lett. 336(2), 113–116 (2003).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60(6), 1259–1287 (2000).
   PubMed Web of Science ®Google Scholar
• Bouchelet I, Case B, Olivier A, Hamel E. No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br. J. Pharmacol. 129(3), 501–508 (2000).
   PubMed Web of Science ®Google Scholar
• Bouchelet I, Cohen Z, Case B, Seguela P, Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol. Pharmacol. 50(2), 219–223 (1996).
   PubMed Web of Science ®Google Scholar
• Classey JD, Bartsch T, Goadsby PJ. Distribution of 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective anti-migraine effect of triptans. Brain Res. 1361, 76–85 (2010).
   PubMed Web of Science ®Google Scholar
• Amrutkar DV, Ploug KB, Hay-Schmidt A, Porreca F, Olesen J, Jansen-Olesen I. mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain 153(4), 830–838 (2012).
   PubMed Web of Science ®Google Scholar
• Bruinvels AT, Landwehrmeyer B, Gustafson EL et al. Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology 33(3–4), 367–386 (1994).
   PubMed Web of Science ®Google Scholar
• Johnson KW, Schaus JM, Durkin MM et al. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 8(9–10), 2237–2240 (1997).
   PubMed Web of Science ®Google Scholar
• Phebus LA, Johnson KW, Zgombick JM et al. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci. 61(21), 2117–2126 (1997).
   PubMed Web of Science ®Google Scholar
• Nelson DL, Phebus LA, Johnson KW et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30(10), 1159–1169 (2010).
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD, Sanchez del Rio M, Waeber C. 5-Hydroxytryptamine(1B/1D) and 5-hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse trigeminal nucleus caudalis. Cephalalgia 22(5), 384–394 (2002).
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD, Sanchez del Rio M, Moskowitz MA, Waeber C. Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur. J. Pharmacol. 369(3), 271–277 (1999).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Classey JD. Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience 122(2), 491–498 (2003).
   PubMed Web of Science ®Google Scholar
• Shepheard S, Edvinsson L, Cumberbatch M et al. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia 19(10), 851–858 (1999).
   PubMed Web of Science ®Google Scholar
• Storer RJ, Goadsby PJ. 5-HT1F agonists inhibit nociceptive transmission at the trigeminocervical complex. Cephalalgia 31(S1), 9–10 (2011).
   Google Scholar
• Goldstein DJ, Roon KI, Offen WW et al. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 358(9289), 1230–1234 (2001).
   PubMed Web of Science ®Google Scholar
• Farkkila M, Diener HC, Geraud G et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 11(5), 405–413 (2012).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Farkkila M, Reuter U et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan–a randomised proof-of-concept trial. Cephalalgia 30(10), 1170–1178 (2010).
   PubMed Web of Science ®Google Scholar
• Andreou AP, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opin. Investig. Drugs 18(6), 789–803 (2009).
   PubMed Web of Science ®Google Scholar
• Storer RJ, Goadsby PJ. Trigeminovascular nociceptive transmission involves N-methyl-D- aspartate and non-N-methyl-D-aspartate glutamate receptors. Neuroscience 90(4), 1371–1376 (1999).
   PubMed Web of Science ®Google Scholar
• Classey JD, Knight YE, Goadsby PJ. The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat. Brain Res. 907(1–2), 117–124 (2001).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Classey JD. Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res. 875(1–2), 6 (2000).
   Web of Science ®Google Scholar
• Charles A, Flippen C, Romero Reyes M, Brennan KC. Memantine for prevention of migraine: a retrospective study of 60 cases. J Headache Pain 8(4), 248–250 (2007).
   PubMed Web of Science ®Google Scholar
• Andreou AP, Holland PR, Goadsby PJ. Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation. Br. J. Pharmacol. 157(3), 464–473 (2009).
   PubMed Web of Science ®Google Scholar
• Andreou AP, Holland PR, Goadsby PJ. Pre- and post-synaptic involvement of GluR5 kainate receptor in the trigeminovascular nociceptive processing. Cephalalgia 27, 605 (2007).
   Web of Science ®Google Scholar
• Weiss B, Alt A, Ogden AM et al. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J. Pharmacol. Exp. Ther. 318(2), 772–781 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson KW, Nisenbaum ES, Johnson MP et al. Innovative drug development for headache disorders: glutamate. In: Innovative drug development for headache disorders. Olesen J, Ramadan NM, (Eds). Oxford University Press, London, 185–194 (2008).
   Google Scholar
• Sang CN, Ramadan NM, Wallihan RG et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 24(7), 596–602 (2004).
   PubMed Web of Science ®Google Scholar
• Holland P, Goadsby PJ. The hypothalamic orexinergic system: pain and primary headaches. Headache 47(6), 951–962 (2007).
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Rainero I, Coppola F et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia 28(7), 714–722 (2008).
   PubMed Web of Science ®Google Scholar
• Holland PR, Akerman S, Goadsby PJ. Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J. Pharmacol. Exp. Ther. 315(3), 1380–1385 (2005).
   PubMed Web of Science ®Google Scholar
• Holland PR, Akerman S, Goadsby PJ. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur. J. Neurosci. 24(10), 2825–2833 (2006).
   PubMed Web of Science ®Google Scholar
• Herring WJ, Snyder E, Budd K et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79(23), 2265–2274 (2012).
   PubMed Web of Science ®Google Scholar
• Sun H, Kennedy WP, Wilbraham D et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 36(2), 259–267 (2013).
   PubMed Web of Science ®Google Scholar
• Hoever P, Hay J, Rad M, Cavallaro M, van Gerven JM, Dingemanse J. Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects. J. Clin. Psychopharmacol. 33(3), 363–370 (2013).
   PubMed Web of Science ®Google Scholar
• Black SW, Morairty SR, Fisher SP, Chen TM, Warrier DR, Kilduff TS. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 36(3), 325–336 (2013).
   PubMed Web of Science ®Google Scholar
• Strecker T, Dux M, Messlinger K. Increase in meningeal blood flow by nitric oxide - interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition. Cephalalgia 22(3), 233–241 (2002).
   PubMed Web of Science ®Google Scholar
• Koulchitsky S, Fischer MJ, De Col R, Schlechtweg PM, Messlinger K. Biphasic response to nitric oxide of spinal trigeminal neurons with meningeal input in rat–possible implications for the pathophysiology of headaches. J. Neurophysiol. 92(3), 1320–1328 (2004).
   PubMed Web of Science ®Google Scholar
• Lambert GA, Hoskin KL, Zagami AS. Nitrergic and glutamatergic neuronal mechanisms at the trigeminovascular first-order synapse. Neuropharmacology 47(1), 92–105 (2004).
   PubMed Web of Science ®Google Scholar
• Afridi SK, Matharu MS, Lee L et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 128(Pt 4), 932–939 (2005).
   PubMed Web of Science ®Google Scholar
• Pardutz A, Multon S, Malgrange B, Parducz A, Vecsei L, Schoenen J. Effect of systemic nitroglycerin on CGRP and 5-HT afferents to rat caudal spinal trigeminal nucleus and its modulation by estrogen. Eur. J. Neurosci. 15(11), 1803–1809 (2002).
   PubMed Web of Science ®Google Scholar
• Dieterle A, Fischer MJ, Link AS, Neuhuber WL, Messlinger K. Increase in CGRP- and nNOS-immunoreactive neurons in the rat trigeminal ganglion after infusion of an NO donor. Cephalalgia 31(1), 31–42 (2011).
   PubMed Web of Science ®Google Scholar
• Pardutz A, Krizbai I, Multon S, Vecsei L, Schoenen J. Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis. Neuroreport 11(14), 3071–3075 (2000).
   PubMed Web of Science ®Google Scholar
• Akerman S, Williamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br. J. Pharmacol. 137(1), 62–68 (2002).
   PubMed Web of Science ®Google Scholar
• Hoskin KL, Bulmer DCE, Lasalandra M, Goadsby PJ. Fos expression in the trigeminocervical complex is reduced by NOS inhibition. Cephalalgia 19(4), 394–394 (1999).
   Web of Science ®Google Scholar
• Offenhauser N, Zinck T, Hoffmann J et al. CGRP release and c-fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion. Cephalalgia 25(3), 225–236 (2005).
   PubMed Web of Science ®Google Scholar
• Lassen LH, Olesen J. Nitric Oxide Synthase activation in inhibition in migraine. In:Headache Pathogenesis: Monoamines, Neuropeptides, Purines and Nitric Oxide. Olesen J, Edvinsson L (Eds). Lippincott-Raven, Philadelphia, 247–255 (1997).
   Google Scholar
• Hoivik HO, Laurijssens BE, Harnisch LO et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 30(12), 1458–1467 (2010).
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Goadsby PJ. New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors. Curr. Treat Options Neurol. 14(1), 50–59 (2012).
   PubMed Web of Science ®Google Scholar
• Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol. 3(8), 475–483 (2004).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48, 1157–1168 (2008).
   PubMed Web of Science ®Google Scholar
• Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J. Neurosci. 7(12), 4129–4136 (1987).
   PubMed Web of Science ®Google Scholar
• Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 8(2), 83–91 (1988).
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Offen WW, Klein EG et al. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 21(2), 102–106 (2001).
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 17(7), 785–790 (1997).
   PubMed Web of Science ®Google Scholar
• Peroutka SJ. Neurogenic inflammation and migraine: implications for the therapeutics. Mol. Interv. 5(5), 304–311 (2005).
   PubMedGoogle Scholar
• Akerman S, Holland PR, Goadsby PJ. Mechanically-induced cortical spreading depression associated regional cerebral blood flow changes are blocked by Na(+) ion channel blockade. Brain Res. 1229, 27–36 (2008).
   PubMed Web of Science ®Google Scholar
• Holland PR, Akerman S, Goadsby PJ. Cortical spreading depression-associated cerebral blood flow changes induced by mechanical stimulation are modulated by AMPA and GABA receptors. Cephalalgia 30(5), 519–527 (2010).
   PubMed Web of Science ®Google Scholar
• Richter F, Ebersberger A, Schaible H-G. Blockade of voltage-gated calcium channels in rat inhibits repetitive cortical spreading depression. Neurosci. Lett. 334, 123–126 (2002).
   PubMed Web of Science ®Google Scholar
• Akerman S, Williamson DJ, Goadsby PJ. Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism. Br. J. Pharmacol. 140(3), 558–566 (2003).
   PubMed Web of Science ®Google Scholar
• Shields KG, Storer RJ, Akerman S, Goadsby PJ. Calcium channels modulate nociceptive transmission in the trigeminal nucleus of the cat. Neuroscience 135(1), 203–212 (2005).
   PubMed Web of Science ®Google Scholar
• Storer RJ, Akerman S, Goadsby PJ. GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex. Br. J. Pharmacol. 134(4), 896–904 (2001).
   PubMed Web of Science ®Google Scholar